Serum Neutralization Ntawm SARS Coronavirus 2 Omicron Sublineages BA.1 Thiab BA.2 Thiab Cellular Immune Responses 3 Lub Hlis Tom Qab Booster Vaccination
Jun 05, 2023
Abstract
Lub hom phiaj:
Peb tau tshawb xyuas cov tshuaj tiv thaiv kab mob hauv lub cev tiv thaiv BA.1 thiab BA.2 Omicron sublineages thiab T cell teb ua ntej thiab 3 lub hlis tom qab kev tswj hwm cov tshuaj tiv thaiv kab mob hauv cov neeg ua haujlwm kho mob (HCWs).
Txoj kev:
HCWs hnub nyoog 18e65 xyoo uas tau txhaj tshuaj tiv thaiv thiab tau txais koob tshuaj tiv thaiv kab mob BNT162b2 tau suav nrog. AntieSARS tus mob coronavirus 2 IgG qib thiab cov lus teb ntawm tes (los ntawm kev soj ntsuam interferon g ELISpot) tau soj ntsuam hauv txhua tus neeg koom nrog, thiab ua rau cov tshuaj tiv thaiv tsis zoo rau Delta, BA.1, thiab BA.2 raug soj ntsuam hauv cov neeg koom nrog tsawg kawg ib qho kev mus ntsib 1 lossis 3. lub hlis tom qab kev tswj hwm ntawm koob tshuaj booster.
Cov txiaj ntsig:
Ntawm 118 HCWs uas tau txais koob tshuaj boost, 102 thiab 84 tus neeg koom tau tuaj koom 1- hli thiab 3- hli mus ntsib, raws li. Ua ntej txhaj tshuaj tiv thaiv kab mob, cov tshuaj tiv thaiv qis qis tiv thaiv Delta, BA.1, thiab BA.2 tsuas yog kuaj tau hauv 39/102 (38.2%), 8/102 ( 7.8 feem pua), thiab 12/102 (11.8 feem pua) cov neeg koom, feem. Thaum 3 lub hlis, neutralizing antibodies tawm tsam Delta, BA.1, thiab BA.2 tau kuaj pom hauv 84/84 (100 feem pua), 79/84 (94 feem pua), thiab 77/84 (92 feem pua) cov neeg koom, feem. Geometric txhais tau tias titres ntawm neutralizing antibodies tiv thaiv BA.1 thiab BA.2 yog 2.2-fold thiab 2.8-fold txo piv nrog rau cov Delta. Los ntawm 1 mus rau 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj, cov neeg koom nrog keeb kwm tsis ntev los no ntawm SARS tus kab mob 2 kab mob (n ¼ 21/84) muaj cov theem tsis tu ncua ntawm S1 reactive tshwj xeeb T hlwb thiab neutralizing antibodies tiv thaiv Delta thiab BA.2 thiab 2. . Conversely, neutralizing antibody titres tawm tsam Delta (2.5-fold txo, p < 0.0001), BA.1 (1.5-fold, p 0.02), thiab BA.2 (2- quav, p < 0.0001) poob ntawm 1 mus rau 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj boost rau cov tib neeg yam tsis muaj kab mob tsis ntev los no.
Kev sib tham:
Cov koob tshuaj txhaj tshuaj txhawb tau muab cov lus teb tseem ceeb thiab zoo sib xws rau BA.1 thiab BA.2.
Omicron sublineages; Txawm li cas los xij, lub cev tiv thaiv kab mob tau poob qis thaum tsis muaj tus kab mob tsis ntev los no.
Taw qhia
Lub Omicron (B.1.1.529) SARS coronavirus 2 (SARS-CoV-2) variant tau tshwm sim thaum xyoo 2021 thiab tau ua tiav sai sai rau qhov sib kis tau zoo heev Delta variant.
Thawj qhov sublineage ntawm qhov sib txawv no, BA.1, tau dhau los ua tseem ceeb hauv Tebchaws Europe thaum Lub Kaum Ob Hlis 2021 thiab Lub Ib Hlis 2022 thiab ua rau muaj kev txhawj xeeb loj txog kev ua tau zoo ntawm cov tshuaj tiv thaiv vim muaj kev khiav tawm ntawm cov tshuaj tiv thaiv tsis zoo. Tseeb tiag, Omicron tau nthuav tawm ntau qhov kev hloov pauv epitopic ntawm cov protein ntau, thiab vim tias muaj cov kab mob coronavirus 2019 (COVID-19) cov tshuaj tiv thaiv tau npaj nrog cov keeb kwm qub, kev ua haujlwm tsis zoo rau Omicron tsis tuaj lossis tsawg heev txawm tias cov neeg txhaj tshuaj [1 ,2] ib.
Cov sublineage tom ntej BA.2 tau hloov pauv sai sai rau yav dhau los hauv Tebchaws Europe ncig lub Peb Hlis 2022 txog Lub Plaub Hlis 2022, thiab cov nqi ntawm cov sublineages tshiab BA.4 thiab BA.5 tau nce los ntawm Lub Rau Hli 2022 [3]. BA.2 tau qhia txog kev xaiv kom zoo dua BA.1, tshwj xeeb tshaj yog txhim kho kev kis tau tus mob, thiab tuaj yeem rov ua rau BA yav dhau los. 1-cov neeg kis tau tus mob [4,5].
Cov ntaub ntawv tsis ntev los no tau qhia tias dhau 6 lub hlis tom qab thawj zaug txhaj tshuaj tiv thaiv kab mob, neutralizing antibodies tiv thaiv Omicron sublineages yog undetectable los yog tsawg heev; Txawm li cas los xij, neutralizing antibody titres tau nce ntau ob peb lub lis piam tom qab kev tswj hwm ntawm koob tshuaj tiv thaiv kab mob (thib peb koob) [6e8].
Hauv txoj kev tshawb no, peb tau soj ntsuam cov lus teb tsis zoo ntawm cov tshuaj tiv thaiv kab mob tiv thaiv BA.1 thiab BA.2 sublineages ntawm Omicron variant nyob rau hauv parallel nrog rau yav dhau los Delta variant nyob rau hauv pawg neeg ua haujlwm kho mob (HCWs) uas tau txhaj tshuaj tiv thaiv thiab tau txais koob tshuaj ntawm BNT162b2 mRNA. tshuaj tiv thaiv (PfizereBioNTech). Tsis tas li ntawd, cov lus teb ntawm cov xov tooj ntawm tes rau SARS-CoV-2 tau tshawb xyuas, thiab qhov tshwm sim ntawm kev kis kab mob tom qab tshuaj xyuas koob tshuaj.
Cov txheej txheem
Txoj kev tshawb no yog ib feem ntawm MONITOCOV-Aging project (Saib xyuas lub cev tiv thaiv kab mob rau BNT162b2 mRNA COVID-19 txhaj tshuaj tiv thaiv rau cov neeg laus), uas cov txheej txheem hloov kho txog cov ntaub ntawv tam sim no tau pom zoo los ntawm Ile-De-France V ( ID-CRB 2021- A00119-32) Pawg neeg saib xyuas kev ncaj ncees.
HCWs tau raug suav nrog hauv txoj kev tshawb fawb yog tias lawv tsis muaj kab mob tseem ceeb thiab tsis muaj tshuaj uas tuaj yeem cuam tshuam rau lawv lub cev tiv thaiv kab mob (xws li cov tshuaj steroids thiab cov tshuaj tiv thaiv kab mob), thiab muaj hnub nyoog 18e65 xyoo. Txhua tus neeg koom tau pib tau txais ob koob tshuaj tiv thaiv BNT162b2 ntawm 3- lub lim tiam ntawm kev txhaj tshuaj. Cov koob tshuaj txhawb nqa tau muab rau cov koom nrog los ntawm Fab Kis cov lus qhia hauv tebchaws (tsawg kawg 6 lub hlis tom qab thawj zaug txhaj tshuaj tiv thaiv kab mob). Cov ntaub ntawv los ntawm cov qauv sau ua ntej thiab 3 lub hlis tom qab thawj qhov tshuaj tiv thaiv tau tshaj tawm yav dhau los [9], thiab cov ntaub ntawv los ntawm cov qauv sau ua ntej kev tswj hwm ntawm cov tshuaj tiv thaiv zoo li ntawm 1 thiab 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj tau tshaj tawm. hauv qhov kev kawm no.
AntieSARS-CoV-2 qib IgG thiab neutralizing cov tshuaj tiv thaiv kab mob (siv cov tshuaj tiv thaiv kab mob nyob hauv nruab nrab) tiv thaiv Delta variant thiab BA.1 thiab BA.2 Omicron sublineages raug soj ntsuam. Cov lus teb ntawm tes raug tshuaj xyuas los ntawm interferon g ELISpot assay.
Thov saib cov ntaub ntawv ntxiv rau cov txheej txheem ntxaws.
Cov txiaj ntsig
Tag nrho ntawm 118 tus neeg uas tau txais koob tshuaj ntxiv tau suav nrog. Cov qauv tau sau tseg 1 lub hlis tom qab kev tswj hwm ntawm koob tshuaj booster rau 102 yam kev kawm, thiab tsuas yog 84 tus neeg tuaj koom nrog 3-hli mus ntsib. Qhov nruab nrab (interquartile range) lub sij hawm nruab nrab ntawm kev txhaj tshuaj thawj zaug (thib ob koob tshuaj) thiab koob tshuaj yog 254 (248e265) hnub.
Peb lub hlis tom qab thawj zaug txhaj tshuaj tiv thaiv kab mob (kuj koob tshuaj 1 thiab 2), qhov nruab nrab theem (interquartile range) ntawm antieSARS-CoV-2 IgG yog 1125 (653e1828) BAU/mL. Tus nqi no poob rau 290 (200e534) BAU / mL ua ntej koob thib peb thiab tom qab ntawd nce siab tshaj 2080 BAU / mL 1 thiab 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj boost (Daim duab 1a). Cov suav ntawm S1 reactive T hlwb kuj nce 1 thiab 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj (Daim duab 1a).
Raws li pom nyob rau hauv daim duab 1b, ua ntej kev tswj hwm ntawm koob tshuaj tiv thaiv kab mob, cov tshuaj tiv thaiv kab mob tsis zoo tiv thaiv Delta, BA.1, thiab BA.2 tsuas yog kuaj tau hauv 39/102 (38.2 feem pua), 8/102 (7.8%), thiab 12/102 (11.8 feem pua) cov neeg koom, feem, nrog qis nruab nrab cov tshuaj tiv thaiv kab mob sib txawv li ntawm 20 txog 160. Geometric txhais tau tias titres (GMTs) tau qis dua qhov txwv ntawm kev kuaj pom ntawm 20 rau txhua qhov sib txawv.
Ib hlis tom qab kev tswj hwm ntawm koob tshuaj, kev ua haujlwm tsis zoo ntawm Delta, BA.1, thiab BA.2 tau pom hauv 102/102 (100%) , 99/102 ( 97 feem pua), thiab 101/102 (99 feem pua) sim sera, feem. Tsis tas li ntawd, GMTs ntawm neutralizing antibodies (95 feem pua CI) tau nce mus rau 465 (373e579) rau Delta, 105 (85e131) rau BA.1, thiab 99 (82e121) rau BA.2, qhia tias GMTs tawm tsam Delta yog 4. .4- quav thiab 4.
Peb lub hlis tom qab kev tswj hwm ntawm koob tshuaj boost, neutralizing antibodies tiv thaiv Delta, BA.1, thiab BA.2 tau kuaj pom hauv 100 feem pua (n ¼ 84/84), 94 feem pua (n ¼ 79/84) , thiab 92 feem pua (n ¼ 77/84) ntawm cov neeg koom, feem, thiab GMTs yog 260 (203e334), 102 (76e136), thiab 69 (54e88), feem. GMTs tawm tsam BA.1 thiab BA.2 yog 2. .
Within 3 months after the administration of the booster dose, a SARS-CoV-2 infection was confirmed or strongly suspected in 21 subjects (presumably Omicron infections because this variant represented >95 feem pua ntawm cov neeg mob nyob rau lub sijhawm no). Tus kab mob no tau lees paub los ntawm qhov txiaj ntsig zoo ntawm RT-PCR cov txiaj ntsig hauv kaum tus neeg, nrog kev kis tus kab mob tshwm sim thaum thawj 4 lub lis piam (1 kev kawm) lossis 8 lub lis piam tom ntej (9 yam lus) tom qab tswj hwm kev txhaj tshuaj tiv thaiv kab mob. Tus kab mob asymptomatic, tsis tau lees paub los ntawm RT-PCR vim li no [10] thiab tsis tuaj yeem kuaj pom los ntawm kev kuaj serological siv cov antigens los ntawm cov kab mob sib kis, tau xav tias muaj kev xav tsis thoob hauv 11 tus neeg ntxiv los ntawm kev nce ntxiv ntawm N reactive tshwj xeeb T hlwb hauv interferon. g ELISpot assay vim tias N protein tsis yog ib qho antigen tsom los ntawm BNT162b2 (Fig. 1c).
Kev tsom xam pab pawg neeg pom tau tias 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj, S1 reactive tshwj xeeb T hlwb (Fig. 1c) thiab neutralizing antibody qib tawm tsam txhua qhov sib txawv tau siab dua nyob rau hauv pab pawg nrog keeb kwm ntawm tus kab mob tom qab koob tshuaj ntau dua li cov neeg koom nrog tsis muaj kab mob tsis ntev los no ( Fig. 1d thiab Table S1). Tseeb tiag, GMT (95 feem pua CI) ntawm neutralizing titres poob los ntawm 1 mus rau 3 lub hlis tom qab kev tswj hwm ntawm cov tshuaj boost rau cov tib neeg uas tsis muaj tus kab mob tsis ntev los no nrog Delta (482 [366e635] vs. 190 [143e252] ; 2.5-fold txo; p < 0. {26}}fold txo; p 0.02), lossis BA.2 variant (104 [81e133] vs. 52 [39e69]; 2-fold txo; p < 0.0001). Hloov pauv, cov neeg koom nrog keeb kwm tsis ntev los no ntawm SARS-CoV-2 tus kab mob tau mob siab rau theem ntawm S1 reactive tshwj xeeb T hlwb thiab neutralizing antibodies tiv thaiv Delta thiab BA.2, thiab neutralizing antibodies tiv thaiv BA.1 nce los ntawm 128.5 (72e229) mus rau 277 (137e557) (2.2-pab nce; p 0.014). (Daim duab 1d thiab Table S1).
Kev sib tham
Hauv txoj kev tshawb no, peb tau soj ntsuam cov tshuaj tiv thaiv kab mob los tiv thaiv Omicron sub-variants. Peb pom tias 8.5 lub hlis (nruab nrab) tom qab thawj chav kawm txhaj tshuaj tiv thaiv nrog ob koob tshuaj tiv thaiv mRNA, HCWs tau pom tias muaj qhov tsis zoo ntawm cov tshuaj tiv thaiv kab mob tsawg heev rau Delta variant thiab BA.1 thiab BA.2 Omicron sublineages. Tom qab kev tswj hwm ntawm koob tshuaj, cov neeg tuaj koom tau nthuav tawm lub peev xwm ua kom muaj zog tsis yog tawm tsam Delta variant nkaus xwb tab sis kuj tawm tsam BA.1 thiab BA.2. Qhov no yog ua raws li qhov kev tshawb pom hauv cov ntaub ntawv dhau los hais txog BA.1 [2,11e15] thiab BA.2 [6e8]. Txawm li cas los xij, qhov nruab nrab neutralizing antibody titres tawm tsam BA.1 thiab BA.2 ntawm 1 thiab 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj txhawb zog tau txo qis dua piv nrog rau yav dhau los Delta variant, qhia txog kev txo qis ntawm kev txhaj tshuaj tiv thaiv kab mob Omicron variant.
Interestingly, 1 lub hlis tom qab kev tswj hwm ntawm koob tshuaj boost, peb tau pom zoo ib yam li neutralizing antibody qib tiv thaiv BA.1 thiab BA.2, qhia tias lub cev tiv thaiv kab mob tshwm sim los ntawm BNT162b2 tshuaj tiv thaiv zoo ib yam rau ob qho tib si variants. Qhov kev tshawb pom no ntawm lub asthiv thaum ntxov tom qab kev tswj hwm ntawm koob tshuaj booster yog pom zoo nrog cov hauv lwm cov lus ceeb toom [6,7]. Txawm li cas los xij, qhov poob qis dhau lub sijhawm zoo li tau tshaj tawm rau kev ua haujlwm tsis zoo tawm tsam BA.2. Qhov kev soj ntsuam no, uas yuav tsum tau lees paub, tuaj yeem piav qhia qee qhov kev nce siab ntawm BA.2 thiab kev hloov pauv ntawm BA.1, uas tej zaum nyob ntawm ntau yam.
Raws li kev cia siab, qhov tshwm sim ntawm tus kab mob SARS-CoV-2 tom qab kev tswj hwm ntawm koob tshuaj boost ua rau lub cev tiv thaiv kab mob muaj zog [9]. Kev saib xyuas lossis txawm tias nce ntxiv hauv kev ua haujlwm ntawm cov tshuaj tiv thaiv kab mob tiv thaiv Omicron sib txawv hauv cov neeg mob uas muaj SARS-CoV-2 kev kis mob tom qab kev tswj hwm ntawm koob tshuaj tiv thaiv qhia tau tias cov tshuaj tiv thaiv kab mob ntxiv tuaj yeem txhim kho kev nco. Qhov kev soj ntsuam no yuav yog vim qhov nthuav dav B cell repertoire thiab nce affinity maturation tom qab ntxiv antigen raug, raws li yav tas los hais [16,17].
Lub zog tseem ceeb ntawm peb txoj kev tshawb fawb yog qhov kev ntsuam xyuas ntawm cov lus teb ntawm tes nrog rau cov lus teb humoral 3 lub hlis tom qab kev tswj hwm ntawm koob tshuaj booster thiab cov txiaj ntsig zoo ntawm cov kab mob postebooster thaum ntxov ntawm kev pheej hmoo ntawm kev tiv thaiv kab mob. Lub ntsiab tsis muaj zog ntawm peb txoj kev tshawb fawb yog tias peb tsis tuaj yeem sib piv cov txiaj ntsig ntawm BNT162b2 nrog rau lwm cov tshuaj tiv thaiv mRNA lossis COVID-19 cov tshuaj tiv thaiv ua ke.
Hauv kev xaus, koob tshuaj tiv thaiv kab mob COVID-19, raws li kev kis tus kab mob antigen ntxiv, tau muab cov lus teb muaj zog tiv thaiv BA.1 thiab BA.2 Omicron sublineages. Txawm li cas los xij, cov lus teb yuav zoo li poob qis thaum lub sijhawm, thiab qhov no yog ib qho ntawm cov laj thawj los xav txog yav tom ntej ntawm SARS-CoV-2 cov tswv yim tshuaj tiv thaiv. Kev cuam tshuam txog kev noj qab haus huv rau pej xeem ntawm cov kev tshawb pom no yog tias yuav tsum muaj kev txhawb nqa ntxiv los tswj lub cev tiv thaiv kab mob zoo ib yam hauv cov tib neeg uas muaj kev pheej hmoo ntawm tus kab mob COVID hnyav-19 nrog qhov tshwm sim tsis ntev los no ntawm sublineages tshiab (BA.4 thiab BA.5. ).
Sau cov nyiaj pab
EKA, JD, BCS, ML, thiab GL tau tsim txoj kev tshawb fawb, sau cov ntaub ntawv, ua cov ntaub ntawv txheeb xyuas, thiab sau thiab kho cov ntawv sau. EKA, JD, BCS, ML, thiab GL ua lub luag haujlwm tag nrho rau kev ncaj ncees ntawm cov ntaub ntawv thiab qhov tseeb ntawm cov ntaub ntawv tsom xam. JL, AG, JT, DL, SM, FV, ArD, DHG, JP, DaD, KF, DoD, LB, AlD, AS, DH, MH, FP, BA, thiab YY koom nrog cov ntaub ntawv txheeb xyuas thiab kho cov ntawv sau. . ML thiab GL tau pab sib npaug rau txoj haujlwm no thiab sib koom kev sau ntawv zoo sib xws. Txhua tus kws sau ntawv tau pom zoo zaum kawg rau cov ntawv xa mus.
Kev tshaj tawm Transparency
Cov kws sau ntawv tshaj tawm tias lawv tsis muaj kev tsis sib haum xeeb. Txoj kev tshawb no tau txais daim ntawv lo ntawm COVID-19 National Research Priority, muab khoom plig los ntawm National Steering Committee on Therapeutic Trials and Other COVID-19 Research (CAPNET). Txoj haujlwm no tau txais kev txhawb nqa los ntawm tsoomfwv Fab Kis los ntawm Txoj Haujlwm Kev Tshawb Fawb d'Avenir (I-SITE ULNE/ANR-16-IDEX-0004 ULNE) tswj hwm los ntawm Agence Nationale de la Recherche thiab kuj tau txais kev txhawb nqa los ntawm kev txhawb nqa. los ntawm GMF nyob rau hauv lub aegis ntawm ANRS-MIE (Agence Nationale de recherche sur le sida et les hepatites, Maladies Infecties siv Emergentes).
Kev lees paub
Peb ua tsaug rau Veronique Betancourt, Virginie Dutriez, Anne Guigo, Coralie Lefebvre, Veronique Lekeux, Marie-Th er ese Meleszka, Catherine Mortka, thiab Anthony Rabat rau lawv txoj kev txhawb nqa thiab Bertrand Accart rau nws txoj kev koom tes (Centre de Ressources BRIF tus lej BB 0033-00030). Peb kuj ua tsaug rau Severine Du Flos, Marie Broyez, Peggy Bouquet, Clementine Rolland, Marion Lecorche, Abeer Shaikh Al Arab, Isa-belle Tonnerre, Floriane Mirgot, Japhete Elenga Koanga, Laurent Schwarb, Emilie Rambaut, thiab tag nrho cov kws saib xyuas neeg mob. Kev kuaj tus neeg mob thiab Mathieu Tronchon rau kev sau cov ntaub ntawv.
Cov ntaub ntawv
[1] Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 cov tshuaj tiv thaiv kab mob ua rau muaj kev tiv thaiv tsis zoo tiv thaiv SARS-CoV-2 Omicron variant. Cell 2022; 185:457e66.
[2] Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Kev khiav dim ntawm SARS-CoV-2 Omicron rau cov tshuaj tiv thaiv kab mob nruab nrab. xwm 2022;602:671e5. https://doi.org/10.1038/s41586-021-04389-z.
[3] SARS-CoV-2 variants of concern as of 25 August 2022. European Center for Disease Prevention and Control. Tau txais los ntawm 31 Lub Yim Hli 2022. https://www.ecdc. europa.eu/en/covid-19/variants-concern.
[4] Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: pov thawj los ntawm cov tsev neeg Danish. medRxiv [Preprint] Tshaj tawm Lub Ib Hlis 30, 2022https://doi.org/10.1101/2022.01.28.22270044.
[5] Stegger M, Edslev SM, Sieber RN, Ingham AC, Ng KL, Tang MHE, et al. Qhov tshwm sim thiab qhov tseem ceeb ntawm Omicron BA.1 kab mob ua raws li BA.2 reinfection. medRxiv [Preprint]. Tshaj tawm rau Lub Ob Hlis 22, 2022https://doi.org/10. 1101/2022.02.19.22271112 ib.
[6] Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med 2022; 386: 1579e80. https://doi.org/10.1056/NEJMc2201849.
[7] Pedersen RM, Bang LL, Madsen LW, Sydenham TV, Johansen IS, Jensen TG, et al. Serum neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 booster vaccination. Emerg Infect Dis 2022; 28:1274e5. https://doi.org/10.3201/eid2806.220503.
[8] Evans JP, Zeng C, Qu P, Faraone J, Zheng YM, Carlin C, et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe 2022; 30: 1093e102. https://doi.org/10.1016/j.chom.2022.04.014.
[9] Demaret J, Lefevre G, Vuotto F, Trauet J, Duhamel A, Labreuche J, et al. Cov neeg mob hnyav SARS-CoV-2 txhim kho cov lus teb T-cell tshwj xeeb dua. Clin Transl Immunol 2020; 9:e1217. https://doi.org/10.1002/cti2.1217.
[10] Vimercati L, Stefanizzi P, De Maria L, Caputi A, Cavone D, Quarato M, et al. Loj-scale IgM thiab IgG SARS-CoV-2 serological soj ntsuam ntawm cov neeg ua hauj lwm saib xyuas kev noj qab haus huv uas muaj ib tug tsawg kis kab mob raws li cov nasopharyngeal swab kuaj nyob rau hauv lub tsev kho mob tsev kawm ntawv Italian: foundations rau pej xeem noj qab haus huv. Environ Res 2021; 195:110793. https://doi.org/10.1016/j.envres.2021.110793.
[11] Jacobsen H, Strengert M, Maaß H, Durand MAY, Kessel B, Harries M, et al. Kev txo qis cov lus teb tsis zoo rau SARS-CoV-2 Omicron VoC tom qab mRNA lossis vector-based COVID-19 txhaj tshuaj tiv thaiv medRxiv [Preprint]. Tshaj tawm 21 Lub Kaum Ob Hlis 2021https://doi.org/10.1101/2021.12.21.21267898.
[12] Perez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. Neutralizing antibodies tiv thaiv SARS-CoV-2 Delta thiab Omicron variants tom qab heterologous CoronaVac ntxiv rau BNT162b2 tshuaj tiv thaiv kab mob. Nat Med 2022; 28:481e5. https://doi.org/10.1038/s41591-022-01705-6.
[13] Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma neutralization of SARS-CoV-2 Omicron variant. N Engl J Med 2022; 386:599e601. https://doi.org/10.1056/NEJMc2119641.
[14] Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, et al. Homologous lossis heterologous booster ntawm cov tshuaj tiv thaiv tsis muaj zog txo SARS-CoV-2 Omicron variant dim ntawm cov tshuaj tiv thaiv tsis zoo. Emerg Microbe. Kab mob 2022; 11: 477e81. https://doi.org/10.1080/22221751.2022.2030200.
[15] Xia H, Zou J, Kurhade C, Cai H, Yang Q, Cutler M, et al. Neutralization thiab durability ntawm 2 lossis 3 koob tshuaj ntawm BNT162b2 tshuaj tiv thaiv Omicron SARSCoV-2. Cell Host Microbe 2022; 30: 485e8.
[16] Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, width, and resilience to viral escape mutations. Kev tiv thaiv 2021; 54: 1853e68.
[17] Muecksch F, Wang Z, Cho A, Gaebler C, Tanfous TB, DaSilva J, et al. Ua kom muaj zog thiab dav ntawm SARS-CoV-2 neutralizing cov tshuaj tiv thaiv tom qab txhaj tshuaj tiv thaiv mRNA thib peb. bioRxiv [Preprint]. Tshaj tawm rau Lub Ob Hlis 15, 2022https://doi. org/10.1101/2022.02.14.480394.
For more information:1950477648nn@gmail.com
